ABT vs WES · P/E 25, rev $44.33B vs P/E 12, rev $3.84B
Abbott Laboratories (ABT) versus Western Midstream Partners LP (WES) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Western Midstream Partners LP (WES) is a oil & gas midstream company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported WES revenue for 2025-12-31 was $3.84B. Net income was $1.18B. Revenue was up 6.6% from 2024-12-31 to 2025-12-31. WES currently screens at market cap $14.85B and trailing P/E 11.7.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. WES currently screens at market cap $14.85B and trailing P/E 11.7.
Not investment advice. Open the ABT and WES stock pages for the full models.
Not investment advice.